The hemolytic activity of the classical complement pathway (CH50) is widely used for screening and monitoring many rheumatic and immunologic diseases such as rheumatoid arthritis, systemic lupus erythematosus, and inherited deficiencies of the complement system [1, 2] . Traditionally, CH50 is evaluated by measuring the ability of serum to lyse antibody-coated sheep erythrocytes. Due to the complicated and time-consuming procedure, several assays have been developed and improved in various studies for simple and automated processing in clinical laboratories [3, 4] . Recently, CH50 liposomebased immunoassay (LIA) have replaced the conventional hemolytic CH50 assay owing to its ease in automation and limited interference caused by bilirubin, hemoglobin, and serum proteins [5] .
To the Editor,
The hemolytic activity of the classical complement pathway (CH50) is widely used for screening and monitoring many rheumatic and immunologic diseases such as rheumatoid arthritis, systemic lupus erythematosus, and inherited deficiencies of the complement system [1, 2] . Traditionally, CH50 is evaluated by measuring the ability of serum to lyse antibody-coated sheep erythrocytes. Due to the complicated and time-consuming procedure, several assays have been developed and improved in various studies for simple and automated processing in clinical laboratories [3, 4] . Recently, CH50 liposomebased immunoassay (LIA) have replaced the conventional hemolytic CH50 assay owing to its ease in automation and limited interference caused by bilirubin, hemoglobin, and serum proteins [5] .
The measurable range and reference interval of the CH50 LIA (Wako, Osaka, Japan) are known to be 10-60 U/mL and 23-46 U/mL, respectively. Additionally, dilution tests using normal saline (NS) reported a good linear relationship with the CH50 LIA [5] . However, samples have been frequently measured above the upper measurable limit (UML). Furthermore, the samples above the UML showed discrepancies in the CH50 values after dilution depending on the dilution ratios. Because of these inconsistent results, we studied the effect of diluent type and dilution ratio and established a new reliable reference interval in the CH50 LIA.
Serum samples collected from eight individuals were used. The samples were stored at -80 °C and thawed in a water bath at 37 °C before use [6] . As diluents, NS, heatinactivated pooled serum (HIPS), and heat-inactivated self-serum (HISS) were tested. Complement-deficient human serum would be the ideal diluent; instead heatinactivated serum was tested as a surrogate to adopt in the routine laboratory process. Heat-inactivation was carried out in a water bath at 56 °C for 30 min followed by cooling immediately in ice [7] . The measurement of CH50 was performed by CA-400 (Furuno, Hyogo, Japan) using Autokit CH50 (Wako, Osaka, Japan).
To evaluate the effect of diluent type, four samples (A, B, C, and D) were manually mixed with three different types of diluents in a volume ratio 1:2. In this study, the dilution ratio was fixed at 1:3. This dilution ratio was selected to show the differences in the recoveries by diluent type. The ratio of 1:3 was used to indicate that one volume of the sample was mixed with two volumes of diluent, resulting in a total volume of three. Also, the dilution factor was 0.33, which was defined as the proportion of sample volume to total volume. A total of 24 points (four samples × three diluents × duplicate) were measured. The percent recovery (%R), which was defined as the proportion of corrected CH50 value to nondiluted CH50 value, was calculated for each measurement.
(diluted value of CH50) %R 100(%) (dilution factor) (non diluted value of CH50) = × × −
The measured CH50 values and %R values were analyzed according to mean and standard deviation (SD) using the program GraphPad Prism version 6.07 (GraphPad Software, San Diego, CA, USA).
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The CH50 values of nondiluted samples (A, B, C, and D) were 38.9, 47.7, 57.6, and 59.3 U/mL, respectively. Additionally, all the CH50 values of the diluents were below the lower measurable limit ( < 10 U/mL). All the data of %R (n = 8; mean±SD; diluent type) of each diluent were calculated to be 90.5±12.9 (NS), 98.5±4.5 (HIPS), and 103.8±3.7% (HISS). The median (center line), mean ('+' sign), 2.5-97.5 percentile (whisker), and 95% confidence interval (CI; box) of %R for each diluent was plotted in Figure 1 . We assumed that self-serum would show better recoveries than pooled serum. However, both HISS and HIPS showed good recoveries whereas NS showed relatively poor and wide ranges of recoveries. Due to the cumbersome process of heat-inactivation and the limitation in the sample volume for each single donor serum, HISS was excluded in the study of dilution ratio. (A) HIPS showed no significant difference in %R by dilution ratio; (B) NS showed optimal recovery at 1:2 ratio (dilution factor 0.50); however, more diluted samples represented poor and wide range of recoveries. *Dilution factor 1.00 indicates no dilution; %R = 100.
Next, the dilution ratio was controlled with two diluents (NS and HIPS). Four samples (E, F, G, and H) were manually mixed in four different dilution ratios 1:4, 1:3, 1:2, and 3:4 (dilution factors 0.25, 0.33, 0.50, and 0.75). The CH50 values of a total of 32 points (four samples × four dilution ratios × duplicate) were measured, and the %R values were calculated. The mean and SD of %R values (n = 8) for each fixed dilution ratio were analyzed using the same method as described earlier. The %R of HIPS was not affected by the difference in dilution ratios (Figure 2A ) while the %R of NS was affected significantly ( Figure 2B) . The values of %R (mean±SD; NS) for each dilution factor (in parentheses) were 51.5±21.3 (0.25), 90.0±10.1 (0.33), 104.9±4.1 (0.50), and 107.5±3.0% (0.75). Among the tested dilution ratios, dilution factor 0.50 (1:2 dilution) showed the best %R with NS; however, more diluted samples showed poor and wide ranges of %R. These results implied that the %R of NS could be affected easily by the dilution ratio; the ratio of 1:2 with NS showed the most acceptable result.
A new reference interval for the CH50 LIA was established. Serum samples obtained from 154 individuals who visited Severance Health Care Center (Seoul, Korea) for healthcare service were used to measure CH50. Because we used the residual serum samples, this study was waived by the Institutional Review Board. The exclusion criteria for the reference population were: (1) diabetes mellitus (HbA 1c > 6.5%); (2) white blood cell (WBC) count ( < 3000/mL or > 12,000/mL); (3) increased level of C-reactive protein (CRP; > 8.0 mg/dL); and (4) severe increased level ( > 100 U/L) of aspartate aminotransferase (AST), alanine aminotransferase (ALT), or γ-glutamyl transpeptidase (GGT); 12 patients were ruled out due to the exclusion criteria. The reference population (n = 142, age mean±SD) consisted of 77 males (43.2±14.7 years) and 65 females (39.5±14.8 years) and showed no statistical difference for gender and age. All samples over the UML were diluted with NS at 1:2 ratio (dilution factor 0.50) to compare with the previous reported results which had been processed using this dilution method empirically. The distribution of CH50 values showed normality based on the Kolmo gorov-Smirnov test at the 5% significance level (D statistic 0.05, p-value 1.0000) using the program Analyse-it for Microsoft Excel 3.80 (Analyse-it Software, Leeds, UK). By taking the 95% CI (mean±2SD) of the reference population, the reference interval was calculated to be 36.0-70.7 U/mL.
Subsequently, 231 reported results of CH50 collected between August 2014 and July 2015 in Severance Hospital (Seoul, Korea) were reviewed. When we applied the manufacturer reference interval (23.0-46.0 U/mL), the numbers of the population below the lower reference limit (LRL), the population within the reference interval, and the population above the upper reference limit were 13 (5.63%), 40 (17.32%), and 178 (77.06%), respectively. Along the same lines, use of the new reference interval (36.0-70.7 U/mL) resulted in population numbers of 23 (9.96%), 173 (74.89%), and 35 (15.15%), respectively. In the retrospective review (n = 231), the manufacturer's reference interval turned out to have a pitfall in patient evaluation for CH50. Significantly, 10 patients were newly classified as being below the LRL from our reference interval. We reviewed the medical conditions of these patients to determine whether the patients showed a low complement condition. All patients showed related medical conditions with low complement activity such as nephrotic syndrome, kidney transplantation, glomerulonephritis, and systemic lupus erythematosus [8] . Additionally, low levels of complement (C3, C4) or immunoglobulin (IgG, IgA, IgM) in these patients were observed. After the medical review of the patients, it was acceptable to consider the new LRL (36.0 U/mL) as a cut-off value for low complement activity status.
Though Yamamoto et al. reported a reference interval of 23-46 U/mL in 160 healthy individuals in Japan [5] ; this reference interval could not be adopted in our institution. In Portugal, the reference interval of the CH50 LIA was reported as 32-63 U/mL, using 100 serum samples obtained from 100 healthy individuals (52 males, 48 females; aged from 21 to 72 years) [9] . Additionally, two major clinical laboratories in the United States (Mayo Medical Laboratories and Quest Diagnostics) have used the CH50 LIA and their reference intervals were 30-75 U/mL and 31-60 U/mL, respectively [10, 11] . Though the dilution method over the UML was unclear, the reference interval of our result was close to that of Mayo Medical Laboratories and all LRL values were higher than the value (23 U/mL) obtained in Japan.
In conclusion, a new reliable reference interval for the CH50 LIA was established in the Korean population: 36.0-70.7 U/mL. The narrow measurable range of the CH50 LIA had evoked the issue of dilution; a sample dilution was revealed to be an essential process required to cover the reference interval using this assay. The study showed that values obtained using HIPS as diluent are not affected by dilution ratio significantly while values using NS are affected except at 1:2 ratio. The results suggest that HIPS is a more optimal diluent than NS in terms of recovery. Hence, we recommend using HIPS to dilute the samples over the UML; however, if NS is used instead of HIPS then the dilution ratio should be 1:2 ratio.
